Format

Send to

Choose Destination
Nucleic Acids Res. 2015 Feb 27;43(4):2353-66. doi: 10.1093/nar/gkv070. Epub 2015 Feb 6.

Luzp4 defines a new mRNA export pathway in cancer cells.

Author information

1
Department of Molecular Biology and Biotechnology, The University of Sheffield, Firth Court, Western Bank, Sheffield, UK.
2
Department of Molecular Biology and Biotechnology, The University of Sheffield, Firth Court, Western Bank, Sheffield, UK Academic Urology Unit, The University of Sheffield, Beech Hill Road, Sheffield, UK.
3
Sheffield Institute for Translational Neuroscience, The University of Sheffield, 385a Glossop Road, Sheffield, UK.
4
Department of Chemical and Biological Engineering, The University of Sheffield, Mappin Street, Sheffield, UK.
5
Academic Urology Unit, The University of Sheffield, Beech Hill Road, Sheffield, UK.
6
Department of Molecular Biology and Biotechnology, The University of Sheffield, Firth Court, Western Bank, Sheffield, UK stuart.wilson@sheffield.ac.uk.

Abstract

Cancer testis antigens (CTAs) represented a poorly characterized group of proteins whose expression is normally restricted to testis but are frequently up-regulated in cancer cells. Here we show that one CTA, Luzp4, is an mRNA export adaptor. It associates with the TREX mRNA export complex subunit Uap56 and harbours a Uap56 binding motif, conserved in other mRNA export adaptors. Luzp4 binds the principal mRNA export receptor Nxf1, enhances its RNA binding activity and complements Alyref knockdown in vivo. Whilst Luzp4 is up-regulated in a range of tumours, it appears preferentially expressed in melanoma cells where it is required for growth.

PMID:
25662211
PMCID:
PMC4344508
DOI:
10.1093/nar/gkv070
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center